Savient Pharmaceuticals to Report Second Quarter 2006 Financial Results on August 9, 2006

Savient will also host a conference call and live webcast onAugust 9, 2006, at 10:00 a.m. EST.

Christopher Clement, President and Chief Executive Officer, willreview highlights for the quarter and outline the Company's progressin advancing its lead drug candidate, Puricase(R) (PEG-uricase) andoverall corporate strategy.

A live webcast of the conference call can be accessed on the"Webcasts" page under the "Investor Relations" section of theCompany's website at www.savientpharma.com. Participants are urged tolog on to the website 15 minutes prior to the scheduled start time toensure that any necessary audio software is functioning properly.

A replay of the webcast will be available on SavientPharmaceuticals' website through September 9, 2006. In addition, atelephonic replay will also be available through August 23, 2006. Thereplay numbers are (800)-642-1687 or (706) 645-9291. The replay accesscode is 3745705

ABOUT SAVIENT

Based in East Brunswick, New Jersey, Savient Pharmaceuticals,Inc., is a specialty pharmaceuticals company and is engaged indeveloping, manufacturing and marketing pharmaceutical products thataddress unmet medical needs in both niche and broader markets. TheCompany's lead product development candidate, Puricase(R)(PEG-uricase), for treatment-failure gout has reported positive Phase1 and 2 clinical data and has entered Phase 3 clinical trials.Savient's experienced management team is committed to advancing itspipeline and expanding its product portfolio by in-licensing latestage compounds and exploring co-promotion and co-developmentopportunities that fit the Company's expertise in specialtypharmaceuticals and initial focus in rheumatology. Savient markets itsproduct Oxandrin(R) (oxandrolone, USP) in the United States. TheCompany's subsidiary, Rosemont Pharmaceuticals Ltd., develops,manufactures, and markets through its own sales force oral liquidformulations of prescription products for the UK pharmaceuticalmarket. Rosemont's product portfolio includes over 100 liquidformulations primarily targeting the geriatric population. Puricase(PEG-uricase) is a registered trademark of Mountain ViewPharmaceuticals, Inc. Further information on the Company can beaccessed by visiting: www.savientpharma.com

(SVNT-E)